BridgeBio Pharma, Inc. Stock 12‑Month Price Target Cut to $109.44, Implies 55% Upside
BridgeBio Pharma's average price target was reduced from $110.47 to $109.44 by 18 analysts, with a range of $88 to $156. This implies a 55% upside from the Oct. 29 closing price. The consensus rating remains 'Buy' among 23 analysts.
How this was made

The 30-second read
Why it matters
The new consensus target reflects a slight downgrade but retains a buy rating, indicating mixed sentiment.
Market read
Analyst target revisions are a routine driver of short‑term price moves in biotech equities.
What to watch
Underlying pipeline progress or upcoming data releases could offset the modest target reduction.
Background
BridgeBio Pharma is a clinical‑stage biotech focused on genetics‑driven diseases. Analyst coverage is relatively concentrated.
Ticker impact
Analyst consensus price target for BridgeBio Pharma was lowered to $109.44, down from $110.47, indicating a fresh downgrade in expectations.
likely downside as investors price in the lower target
A fresh analyst price‑target reduction is new information that can trigger short‑term selling pressure.
Market effects
May slightly temper sentiment toward biotech stocks reliant on analyst coverage.
Limited to U.S. markets where BBIO trades.
Minimal
Counterpoint
The target cut is modest; the stock still shows 55% upside from current price, suggesting potential for a rebound.
Key entities
- companyBridgeBio Pharma, Inc.
Clinical‑stage biotech company whose price target was adjusted.



